Barclays lowered the firm’s price target on Cytokinetics (CYTK) to $53 from $55 and keeps an Overweight rating on the shares following the Q1 report.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYTK:
- Cytokinetics Receives Buy Rating Amid Positive Outlook for Aficamten and Strong Financial Position
- Cytokinetics’ Earnings Call: Balancing Progress and Challenges
- Cytokinetics Buy Rating: Strategic Developments and Market Opportunities Drive Optimism Despite FDA Delay
- Cytokinetics: Strong Financials and Promising Pipeline Drive Buy Rating
- Cytokinetics price target lowered to $80 from $86 at Citi
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue